Stem Cell Therapy Market Size, Growth, Statistics Report 2028

Stem Cell Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Adult Stem Cell Therapy, Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, and Other Stem Cell Therapy), Treatment (Allogeneic and Autologous), Application (Musculoskeletal, Dermatology, Cardiology, Drug Discovery & Development, and Other Applications), and End User (Hospitals & Specialty Clinics and Academic & Research Institutes), and Geography

  • Report Code : TIPHE100000991
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 206
Buy Now

The stem cell therapy market is expected to grow from US$ 2,278.49 million in 2022 to US$ 6,206.89 million by 2028; it is estimated to grow at a CAGR of 18.2% from 2022 to 2028.

Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under a controlled environment in the body or a clinical laboratory, these cells divide to form more cells, called daughter cells. With the advent of modern health science, these cells have been demonstrated to play a major role in understanding the occurrence of diseases, the generation of advanced regenerative medicines, and the discovery of other drugs. Stem cells are formed in embryos, bone marrow, body fats, and umbilical cord blood, among others.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Stem Cell Therapy Market: Strategic Insights

Stem Cell Therapy Market

  • CAGR (2022 - 2028)
    18.2%
  • Market Size 2022
    US$ 2.28 Billion
  • Market Size 2028
    US$ 6.21 Billion

Market Dynamics

GROWTH DRIVERS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
FUTURE TRENDS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
OPPORTUNITIES
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX

Key Players

  • MEDIPOST
  • RichSource
  • BioTime, Inc.
  • Mesoblast Limited
  • Holostem Terapie Avanzate Srl
  • U.S. Stem Cell, Inc.
  • TiGenix NV
  • AlloSource
  • NuVasive Inc

Regional Overview

  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Type
  • Adult Stem Cell Therapy
  • Embryonic Stem Cell Therapy
  • Induced Pluripotent Stem Cell Therapy
  • Other Stem Cell Therapy
Treatment
  • Allogeneic and Autologous
Application
  • Musculoskeletal
  • Dermatology
  • Cardiology
  • Drug Discovery & Development
  • Other Applications
End User
  • Hospitals & Specialty Clinics and Academic & Research Institutes
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights

Increasing Organic and Inorganic Strategies by Key Players

The key market players are taking up various organic and inorganic strategies, including mergers and acquisitions, expansions, and new product launches, to stay competitive in the market.

  • In October 2022, Medipost (CEO Won-Il Oh) announced the launch of its Contract Development and Manufacturing Organization (CDMO) business for cell and gene therapy products in Korea. The company announced its new GMP facilities will house 10 cleanrooms and production facilities equipped with up-to-date equipment exclusively for CDMO.
  • In December 2019, Lineage Cell Therapeutics and AgeX Therapeutics, in partnership, registered a US patent for the method of generating induced pluripotent stem cells.
  • In June 2021, Allogene Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma. The FDA granted Fast Track designation based on the potential of ALLO-605 to address the unmet need for patients who have failed other standard multiple myeloma therapies.

Thus, many organic and inorganic strategies in the stem cell therapy market enable healthcare professionals to provide improved services.

Lucrative Regions in Stem Cell Therapy Market

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Stem cell therapy has been widely investigated across the world. Stem cells are mainly used to replace dying cells and reconstruct damaged tissues. Based on the results of extensive stem cell research conducted so far, many scientists have claimed that these cells could probably be utilized to generate cures and treatments for diseases such as cancer and cardiovascular disease. Newly developed stem cell therapies involve replacing disease-causing cells with stem cells. Many potential treatments involving stem cells are in different phases of clinical trials. The FDA has also approved a few stem cell therapies involved in treating complications related to stem cell transplants. In September 2021, the US Food and Drug Administration (FDA) announced approval for "Ruxolitinib" for treating "graft-versus-host-disease" (GVHD) in patients aged 12 and above. Ruxolitinib provides a patient new hope that suffers from fatal complications associated with stem cell transplants.

Researchers are further investigating the use of stem cell therapy in treating autoimmune disorders. For example, stem cells can turn into the cells of damaged organs and are used in treating autoimmune diseases. Treatment is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic stem cells are currently used for treating more than 80 medical conditions, including immune system diseases; blood disorders; neurological disorders; metabolic disorders; genetic disorders; and cancer types such as leukemia and lymphoma.

Type Insights

Based on type, the stem cell therapy market is segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and other stem cell therapy. The adult stem cell therapy segment held the largest market share in 2021. However, the induced pluripotent stem cell therapy segment is anticipated to register the highest CAGR during the forecast period (2022–2028).

Treatment Insights

Based on treatment, the global stem cell therapy market is bifurcated into allogeneic and autologous. The allogenic segment held the larger stem cell therapy market share in 2021. Moreover, the autologous segment is expected to grow at the highest CAGR during the forecast period.

Application Insights

In terms of application, the stem cell therapy market is divided into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications. The drug discovery and development segment held the largest market share in 2021, and it is expected to register the highest CAGR during the forecast period.

Stem Cell Therapy Market, by Type – 2021 and 2028

biotechnology
Stem Cell Therapy Market, by Type – 2021 and 2028
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

End User Insights

Based on end user, the stem cell therapy market is bifurcated into academic & research institutes and hospitals & clinics. The academic & research institutes segment held a larger market share in 2021, and the same segment is expected to register a higher CAGR in the market during the forecast period (2022–2028).

Companies in the stem cell therapy market majorly adopt inorganic strategies such as mergers and acquisitions. A few of the recent key developments in the market are listed below.

  • In June 2021, the USFDA granted Fast Track designation to ALLO-605, the next-generation AlloCAR T therapy offered by Allogene Therapeutics, Inc., targeting BCMA for the treatment of relapsed or refractory multiple myeloma. The designation was granted on the basis of the potential of ALLO-605 to address the unmet needs of patients who didn’t respond to other standard multiple myeloma therapies.
  • In June 2021, MEDIPOST announced that the company has expanded the production facilities for its knee osteoarthritis stem cell products, CARTISTEM and SMUP-IA-01, and will start preparing for GMP (Good Manufacturing Practice) certification.
  • In September 2022, Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc. and will focus primarily on advancing its CendR Platform technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs.
  • In March 2019, BioTime, Inc acquired Asterias Biotherapeutics, Inc. which deals in regenerative medicines to consolidate its stem cell therapies product portfolio.

Company Profiles

  • MEDIPOST
  • Pharmicell Co., Inc.
  • RichSource
  • BioTime, Inc.
  • Mesoblast Limited
  • Holostem Terapie Avanzate Srl
  • U.S. Stem Cell, Inc.
  • Caladrius Biosciences, Inc.
  • TiGenix NV
  • AlloSource

Stem Cell Therapy Market Report Scope

Report Attribute Details
Market size in 2022 US$ 2.28 Billion
Market Size by 2028 US$ 6.21 Billion
Global CAGR (2022 - 2028) 18.2%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By Type
  • Adult Stem Cell Therapy
  • Embryonic Stem Cell Therapy
  • Induced Pluripotent Stem Cell Therapy
  • Other Stem Cell Therapy
By Treatment
  • Allogeneic and Autologous
By Application
  • Musculoskeletal
  • Dermatology
  • Cardiology
  • Drug Discovery & Development
  • Other Applications
By End User
  • Hospitals & Specialty Clinics and Academic & Research Institutes
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • MEDIPOST
  • RichSource
  • BioTime, Inc.
  • Mesoblast Limited
  • Holostem Terapie Avanzate Srl
  • U.S. Stem Cell, Inc.
  • TiGenix NV
  • AlloSource
  • NuVasive Inc
    • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    Type, Treatment, Application, and End User

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

    Frequently Asked Questions


    What is meant by the stem cell therapy market?

    Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryo, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated.

    What are the driving factors for the stem cell therapy market across the globe?

    Increasing research activities related to stem cell therapy for effective disease management and growing prevalence of cancer are the most significant factors responsible for the overall market growth.

    Which type segment led the stem cell therapy market?

    Based on type segment, the adult stem cell therapy segment took the forefront leaders in the worldwide market by accounting largest share in 2021 and is expected to continue to do so till the forecast period.

    Which treatment segment held the largest market share in the stem cell therapy market?

    Based on the treatment, allogenic segment took the forefront leaders in the worldwide market by accounting largest share in 2021.

    Which end user segment held the largest market share in the stem cell therapy market?

    Academic & Research institutes segment dominated the global stem cell therapy market and accounted for the largest market share during the forecast period of 2022-2028.

    Who are the key players in the stem cell therapy market?

    MEDIPOST, RichSource, BioTime, Inc., Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., TiGenix NV, AlloSource, NuVasive Inc, JCR Pharmaceuticals Co. Ltd. and among others are among the leading companies operating in the stem cell therapy market.

    What is the regional market scenario of the stem cell therapy market?

    Global stem cell therapy market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

    The List of Companies - Stem Cell Therapy Market

    1. MEDIPOST
    2. RichSource
    3. BioTime, Inc.
    4. Mesoblast Limited
    5. Holostem Terapie Avanzate Srl
    6. U.S. Stem Cell, Inc.
    7. TiGenix NV
    8. AlloSource
    9. NuVasive Inc
    10. JCR Pharmaceuticals Co. Ltd.

    The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

    1. Data Collection and Secondary Research:

    As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

    Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

    1. Primary Research:

    The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

    For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

    A typical research interview fulfils the following functions:

    • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
    • Validates and strengthens in-house secondary research findings
    • Develops the analysis team’s expertise and market understanding

    Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

    • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
    • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

    Below is the breakup of our primary respondents by company, designation, and region:

    Research Methodology

    Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

    1. Data Analysis:

    Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

    • 3.1 Macro-Economic Factor Analysis:

    We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

    • 3.2 Country Level Data:

    Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

    • 3.3 Company Profile:

    The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

    • 3.4 Developing Base Number:

    Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

    1. Data Triangulation and Final Review:

    The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

    We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

    We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Trends and growth analysis reports related to Stem Cell Therapy Market